" class="no-js "lang="en-US"> Lengo Therapeutics - Medtech Alert
Sunday, February 05, 2023

Breaking News

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest enGene Appoints Alex Nichols, PhD as President and Chief Operating Officer Orexo Submits New Drug Application to FDA for OX124, a High-dose Rescue Medication for Opioid Overdose Abbott Announces US and European Approvals for New Technologies to Support Effective Treatment for Abnormal Heart Rhythms RefleXion Receives FDA Clearance for Biology-Guided Radiotherapy Treatment for Early and Late-stage Cancers Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
Lengo Therapeutics | Pharmtech Focus

Lengo Therapeutics

About Lengo Therapeutics

Lengo Therapeutics

Lengo Therapeutics is a biopharmaceutical company committed to developing novel, best-in-class precision medicines targeting driver mutations in oncology to improve the lives of patients with cancer.

Related Story

Diseases

 Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics | Pharmtech Focus

Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics

November 29 2021

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has entered into a definitive agreement […]